

Supplement 1


Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017Gulfaraz Khan, PhD^{1*}, Christina Fitzmaurice, MD², Mohsen Naghavi, PhD², Luai A. Ahmed, PhD³¹Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates²Institute of Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA³Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

* Corresponding author


Contents

Supplementary Information	1
eFigure 1. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributable malignancies in 2017 by location	2
eFigure 2. Global burden of incidence of EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) nasopharyngeal carcinoma (D) gastric carcinoma in 2017 by gender and age.....	3
eFigure 3. Global burden of mortality from EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) nasopharyngeal carcinoma (D) gastric carcinoma in 2017 by gender and age.....	4
eFigure 4. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed Burkitt lymphoma cases in 2017 by world regions	5
eFigure 5. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed Hodgkin lymphoma cases in 2017 by world regions	6
eFigure 6. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed nasopharyngeal carcinoma cases in 2017 by world regions.....	7
eFigure 7. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed gastric cancer cases in 2017 by world regions.....	8
eFigure 8: Global burden of DALYs for EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) Nasopharyngeal carcinoma (D) Gastric carcinoma in 2017 by SDI world regions	9


eFigure 1. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributable malignancies in 2017 by location




eFigure 2. Global burden of incidence of EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) nasopharyngeal carcinoma (D) gastric carcinoma in 2017 by gender and age




eFigure 3. Global burden of mortality from EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) nasopharyngeal carcinoma (D) gastric carcinoma in 2017 by gender and age




eFigure 4. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed Burkitt lymphoma cases in 2017 by world regions




eFigure 5. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed Hodgkin lymphoma cases in 2017 by world regions



eFigure 6. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed nasopharyngeal carcinoma cases in 2017 by world regions



eFigure 7. Global burden of (A) incidence (B) deaths (C) DALYs for EBV-attributed gastric cancer cases in 2017 by world regions



eFigure 8. Global burden of DALYs for EBV-attributed (A) Burkitt lymphoma (B) Hodgkin lymphoma (C) Nasopharyngeal carcinoma (D) Gastric carcinoma in 2017 by SDI world regions

